From: Prediction of primary non-response to methotrexate therapy using demographic, clinical and psychosocial variables: results from the UK Rheumatoid Arthritis Medication Study (RAMS)
Cut-off
Predicted non-responders
Sen
Spec
PPV
NPV
0.5
303 (36%)
59%
80%
68%
72%
0.6
210 (25%)
45%
89%
75%
69%
0.7
123 (15%)
30%
96%
86%
65%
0.8
49 (6%)
14%
100%
98%
61%
0.9
13 (2%)
4%